These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10877737)

  • 21. HIV trial stopped early after good results.
    Boulton A
    BMJ; 1997 Mar; 314(7082):699. PubMed ID: 9116542
    [No Abstract]   [Full Text] [Related]  

  • 22. HIV postexposure prophylaxis after sexual assault: why is it so hard to accomplish?
    Cohen MS
    Sex Transm Dis; 2008 Dec; 35(12):979-80. PubMed ID: 18955917
    [No Abstract]   [Full Text] [Related]  

  • 23. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
    Flandre P; Peytavin G; Meiffredy V; Saidi Y; Descamps D; Delagnes M; Brun-Vézinet F; Raffi F;
    Antivir Ther; 2002 Jun; 7(2):113-21. PubMed ID: 12212923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
    Jankelevich S; Mueller BU; Mackall CL; Smith S; Zwerski S; Wood LV; Zeichner SL; Serchuck L; Steinberg SM; Nelson RP; Sleasman JW; Nguyen BY; Pizzo PA; Yarchoan R
    J Infect Dis; 2001 Apr; 183(7):1116-20. PubMed ID: 11237839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral chemotherapy.
    Saag MS; Schooley RT
    Curr Clin Top Infect Dis; 1998; 18():154-79. PubMed ID: 9779354
    [No Abstract]   [Full Text] [Related]  

  • 26. Transmission of drug-resistant HIV after an occupational exposure despite postexposure prophylaxis with a combination drug regimen.
    Beltrami EM; Luo CC; de la Torre N; Cardo DM
    Infect Control Hosp Epidemiol; 2002 Jun; 23(6):345-8. PubMed ID: 12083242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost of preventing HIV infection after sexual exposure.
    Lindbloom EJ; Stevermer JJ
    J Fam Pract; 1998 Oct; 47(4):251-2. PubMed ID: 9789505
    [No Abstract]   [Full Text] [Related]  

  • 28. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
    Smith D; Berrey MM; Robertson M; Mehrotra D; Markowitz M; Perrin L; Clumeck N; Lazzarin A; Burckhardt B; Weber R; Corey L; Cooper DA
    J Infect Dis; 2000 Sep; 182(3):950-4. PubMed ID: 10950796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effortless unintentional smoking cessation after lamivudine-zidovudine-indinavir post-exposure anti-HIV chemoprophylaxis.
    Simini B; Lucchesi C
    Addiction; 1999 Jan; 94(1):139-40. PubMed ID: 10665106
    [No Abstract]   [Full Text] [Related]  

  • 30. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
    N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.
    Kakuda TN; Page LM; Anderson PL; Henry K; Schacker TW; Rhame FS; Acosta EP; Brundage RC; Fletcher CV
    Antimicrob Agents Chemother; 2001 Jan; 45(1):236-42. PubMed ID: 11120972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir.
    Gisslén M; Norkrans G; Svennerholm B; Hagberg L
    AIDS; 1998 Jan; 12(1):114-6. PubMed ID: 9456264
    [No Abstract]   [Full Text] [Related]  

  • 33. The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome.
    Clarke SM; Mulcahy F; Healy CM; Condon S; Butler KM
    Int J STD AIDS; 2000 Apr; 11(4):220-3. PubMed ID: 10772084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double protease inhibitor regimens with amprenavir show promise.
    AIDS Patient Care STDS; 1998 Apr; 12(4):317-8. PubMed ID: 11361962
    [No Abstract]   [Full Text] [Related]  

  • 35. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy.
    Clark NM; Dieng Sarr A; Sankalé JL; Kanki PJ; Kazanjian P; Winfield R; Markovitz DM
    AIDS; 1998 Dec; 12(18):2506-7. PubMed ID: 9875594
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-HIV effects of nelfinavir reported after ten months of combination therapy.
    AIDS Patient Care STDS; 1997 Aug; 11(4):289-90. PubMed ID: 11361848
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance.
    Sonder GJ; Prins JM; Regez RM; Brinkman K; Mulder JW; Veenstra J; Claessen FA; van den Hoek A
    Sex Transm Dis; 2010 Nov; 37(11):681-6. PubMed ID: 20644499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New recommendations on health care worker exposure to HIV.
    Woodward J
    STEP Perspect; 1996; 8(3):8-10. PubMed ID: 11364268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamivudine 300 mg in HIV infection: dose change. Once-a-day dosing.
    Prescrire Int; 2004 Apr; 13(70):54. PubMed ID: 15148972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.